Cargando…

ETS-targeted therapy: can it substitute for MEK inhibitors?

BACKGROUND: The RAS/MAPK pathway has been intensively studied in cancer. Constitutive activation of ERK1 and ERK2 is frequently found in cancer cells from a variety of tissues. In clinical practice and clinical trials, small molecules targeting receptor tyrosine kinases or components in the MAPK cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tetsu, Osamu, McCormick, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418169/
https://www.ncbi.nlm.nih.gov/pubmed/28474232
http://dx.doi.org/10.1186/s40169-017-0147-4